Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized... | NCT07739147

NCT07739147

Overview

NCT ID: NCT07739147
Lead Sponsor: Kimberly MeathrelINDUSTRY
Official Title: Photobiomodulated Platelet-Rich Plasma for Androgenetic Alopecia: A Randomized Controlled Trial Comparing Standard PRP vs Red-Light Enhanced vs Blue-Light Enhanced PRP Using the MetaCell Technologies System
Brief Summary: The goal of this clinical trial is to compare 3 different types of PRP in androgenetic alopecia patients. The main questions it aims to answer:

Does Redlight enhanced, Blue light enhanced, or traditional PRP result in higher hair density and health? Does Redlight enhanced, Blue light enhanced, or traditional PRP result in other improved hair metrics.

Participants will consent to a PRP treatment but will be blinded to the type. They will then be asked to return for Tricholab analysis at set post-operative timepoints to record changes in hair metrics (Baseline, 1 month, 3 months, 6 months, 9 months, 12 months).
Conditions: Androgenetic Alopecia

Status and Timeline

Status: Not yet recruiting
Last Update Posted: Jul 31, 2026Actual
Start Date: Dec 30, 2026Estimated
Primary Completion Date: Dec 30, 2027Estimated
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Age 18-65

Diagnosed Androgenetic Alopecia

Willing to comply with protocol and follow up

Exclusion Criteria:

Active scalp infection or disease

Prior PRP within last 6 months

Use of hair growth medication topical or oral

Platelet dysfunction or anticoagulation

Pregnant or breastfeeding

history of keloid infection

Study Plan

Study Type: Interventional
Phase: Early Phase 1
Enrollment: 30Estimated
Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Triple

Contacts and Locations

Central Contacts: Kimberly E Meathrel, MD, JD, MBA, MSc, FRCSCContact
admin@bespokeskinmd.com

Similar Studies

Participant Group/Arms

Standard PRPExperimental

Participants assigned to this arm receive autologous PRP injection alone, prepared from their own peripherally drawn injected into the scalp. No adjunctive light therapy or cooling is applied in this arm. (Intervention 1 only)

Drug: Platelet-Rich Plasma (PRP) Injections

Red-Light Enhanced PRPExperimental

Participants assigned to this arm receive autologous PRP injection, prepared and administered as Arm 1, immediately followed by red-light photobiomodulation therapy delivered via the MetaCell Technologies System, combined with cooling. (Intervention 1 and 2)

Drug: Platelet-Rich Plasma (PRP) Injections

Blue-Light Enhanced PRPExperimental

Participants assigned to this arm receive autologous PRP injection, prepared and administered as intervention 1, immediately followed by blue-light photobiomodulation therapy delivered via the MetaCell Technologies System with heating. (Intervention 1 and 3)

Drug: Platelet-Rich Plasma (PRP) Injections